1stOncology™: Cancer Intelligence Service – Page 17345 – 1stOncology is recognized as a Top 10 Global Pharma Analytic Provider

10-Q – Quarterly report [Sections 13 or 15(d)]

Ligand has filed a 10-Q – Quarterly report [Sections 13 or 15(d)] with the U.S. Securities and Exchange Commission (Filing, 10-Q, Ligand, MAY 11, 2015, View Source [SID1234504186]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

Schedule Your 30 min Free Demo!

10-Q – Quarterly report [Sections 13 or 15(d)]

KaloBios has filed a 10-Q – Quarterly report [Sections 13 or 15(d)] with the U.S. Securities and Exchange Commission (Filing, 10-Q, KaloBios, MAY 11, 2015, View Source [SID1234504184]).

10-Q – Quarterly report [Sections 13 or 15(d)]

Idera Pharmaceuticals has filed a 10-Q – Quarterly report [Sections 13 or 15(d)] with the U.S. Securities and Exchange Commission (Filing, 10-Q, Idera Pharmaceuticals, MAY 11, 2015, View Source [SID1234504182]).

10-Q – Quarterly report [Sections 13 or 15(d)]

Galectin Therapeutics has filed a 10-Q – Quarterly report [Sections 13 or 15(d)] with the U.S. Securities and Exchange Commission (Filing, 10-Q, Galectin Therapeutics, MAY 11, 2015, View Source [SID1234504181]).

Provenge – Withdrawal of the marketing authorisation in the European Union

On 6 May 2015, the European Commission withdrew the marketing authorization for Provenge in the European Union (EU) (European Medicines Agency, MAY 11, 2015, View Source [SID:1234511747]). The withdrawal was at the request of Dendreon, which notified the European Commission of its decision to permanently discontinue the marketing of the product for commercial reason.